2-氨基-3-三氟甲基-5-溴吡啶 | 79456-34-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-3-三氟甲基-5-溴吡啶
• 中文别名: 2-氨基-5-溴-3-(三氟甲基)吡啶；5-溴-3-三氟甲基-2-氨基吡啶
• 英文名称: 5-bromo-3-(trifluoromethyl)pyridin-2-amine
• 英文别名: 5-bromo-3-trifluoromethyl-pyridin-2-ylamine
• CAS: 79456-34-1
• 化学式: C₆H₄BrF₃N₂
• 分子量: 241.01
• InChiKey: QUYZBNHTYCLZLW-UHFFFAOYSA-N

物化性质

• 熔点：
  90 °C
• 沸点：
  216.6±35.0 °C(Predicted)
• 密度：
  1.790±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温条件下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Amino-5-bromo-3-trifluoromethylpyridine
Product Name:
Synonyms: 5-Bromo-3-(trifluoromethyl)pyridin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Amino-5-bromo-3-trifluoromethylpyridine
Ingredient name:
CAS number: 79456-34-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4BrF3N2
Molecular weight: 241.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

2-氨基-3-三氟甲基-5-溴吡啶是一种有机中间体，可以通过2-氨基-3-三氟甲基吡啶的溴代反应得到。

制备

将化合物BB-21-1（42.0 g，259 mmol）溶解于氮气氛围下的N,N-二甲基甲酰胺（400 mL），然后加入N-溴代丁二酰亚胺（46.1 g，259 mmol）。反应物在20℃下搅拌2小时。随后，将反应液倒入混合有5%亚硫酸氢钠和水（体积比为10:1）的搅拌溶液中，析出产物并过滤，用水洗涤后溶于二氯甲烷（500 mL），使用无水硫酸钠干燥，滤除固体，浓缩得到目标化合物2-氨基-3-三氟甲基-5-溴吡啶（黄色固体，51.0 g，收率：89.7%）。其核磁共振氢谱数据为：1H NMR (400 MHz, CDCl₃) δ 8.27 (s, 1H)，7.80 (s, 1H)，5.02 (br, 2H)。质谱数据为：ESI-MS m/z 241 [M+H]+，243 [M+H₂⁺]。

反应信息

• 作为反应物：
  描述：

  2-氨基-3-三氟甲基-5-溴吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, INTERMEDIATES AND POLYMORPHS THEREOF
  [FR] PROCÉDÉ POUR LA PRÉPARATION DE COMPOSÉS D'IMIDAZO[4,5-C]QUINOLINE SUBSTITUÉS, D'INTERMÉDIAIRES ET DE POLYMORPHES DE CEUX-CI

  摘要：

  本发明涉及一种制备取代咪唑并[4,5-c]喹啉化合物（如所述的化合物I的化合物）及其中间体的方法。本发明还涉及化合物I中包含的化合物的多晶形态及其在治疗增殖性疾病，特别是癌症中的应用。

  公开号：

  WO2015145369A1
• 作为产物：
  描述：

  2-氨基-3-三氟甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以99%的产率得到2-氨基-3-三氟甲基-5-溴吡啶
  参考文献：
  名称：

  适合合成的双亮氨酸拉链激酶（DLK）抑制剂GNE-834

  摘要：

  开发了一种实用的双亮氨酸拉链激酶（DLK）抑制剂GNE-834（1）的合成方法。关键的C C键是通过Suzuki-Miyaura的碘吡唑2和吡啶硼酸酯3的交叉偶联而得到的，从而得到酮12。随后用吗啉对酮12进行选择性还原胺化，然后通过甲苯磺酸盐的形成进行拆分，从而提供了GNE-834（1），其碘化物2的总收率为39％，HPLC纯度为98.9 A％。

  DOI：

  10.1016/j.tetlet.2020.152430

文献信息

• [EN] HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES<br/>[FR] SULFONES À HÉTÉROCYCLYLES À SUBSTITUTION HÉTÉROARYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2015158427A1

  公开（公告）日：2015-10-22

  The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及芳基取代的杂环磺酮作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
  作者：Aurélie Mallinger、Kai Schiemann、Christian Rink、Frank Stieber、Michel Calderini、Simon Crumpler、Mark Stubbs、Olajumoke Adeniji-Popoola、Oliver Poeschke、Michael Busch、Paul Czodrowski、Djordje Musil、Daniel Schwarz、Maria-Jesus Ortiz-Ruiz、Richard Schneider、Ching Thai、Melanie Valenti、Alexis de Haven Brandon、Rosemary Burke、Paul Workman、Trevor Dale、Dirk Wienke、Paul A. Clarke、Christina Esdar、Florence I. Raynaud、Suzanne A. Eccles、Felix Rohdich、Julian Blagg

  DOI：10.1021/acs.jmedchem.5b01685

  日期：2016.2.11

  complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine

  介体复合物相关的细胞周期蛋白依赖性激酶 CDK8 与人类疾病有关，特别是在结肠直肠癌中，据报道它是一种推定的癌基因。在这里，我们报告了109 (CCT251921) 的发现，它是一种有效的、选择性的和口服生物可利用的 CDK8 抑制剂，对 CDK19 具有等效的亲和力。我们描述了一种基于结构的设计方法，导致发现了 3,4,5-三取代-2-氨基吡啶系列，并介绍了物理化学性质分析的应用，以成功降低体内代谢清除率，最大限度地减少转运蛋白介导的胆汁消除，同时保持可接受的水溶性。化合物109提供了体外生化、药代动力学和物理化学性质的最佳折衷，并适用于发展为癌症动物模型。
• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150259357A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention

  本发明涉及式（I）的化合物，或其形式，其中环A，R1，R2，R3，R3'，L，W和V如本文所定义，可用作FLAP调节剂。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• [EN] BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS BICYCLO[1.1.1]PENTANE DE LA DOUBLE FERMETURE À GLISSIÈRE DE LEUCINE KINASE (DLK) DESTINÉS AU TRAITEMENT DE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2018107072A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy -induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

  本文披露了抑制双亮氨酸拉链（DLK）激酶（MAP3K12）激酶活性的化合物、药物组合物以及治疗DLK介导疾病的方法，例如由于对中枢神经系统和外周神经系统神经元的创伤性损伤而导致的神经系统疾病（例如中风、创伤性脑损伤、脊髓损伤），或由于慢性神经退行性疾病（例如阿尔茨海默病、额颞叶痴呆、帕金森病、亨廷顿病、肌萎缩侧索硬化、脊髓小脑共济失调、进行性上行性麻痹、路易体病、肯尼迪病及其他相关疾病）引起的疾病，以及由神经损伤引起的神经病（化疗诱导的周围神经病、糖尿病神经病及相关疾病）和由药物干预引起的认知障碍（例如化疗诱导的认知障碍，也称为化疗脑）。
• Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
  申请人：Baskaran Subramanian

  公开号：US20100204265A1

  公开（公告）日：2010-08-12

  Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

  提供了一些化学实体、药物组合物以及治疗黄病毒科家族成员，如肝病毒（丙型肝炎或HCV）的方法。